Unit 09, Office Tower
41st Floor, Room 4109 Convention Plaza 1 Harbour Road
Wan Chai
Hong Kong
852 2802 9886
https://www.sinobiopharm.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 26,079
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Ms. Y. Y. Tse | Executive Chairwoman of the Board | 38.75M | N/A | 1992 |
Mr. Eric S. Y. Tse | CEO & Executive Director | 25.47M | N/A | 1996 |
Mr. Ping Tse | Founder & Senior Executive Vice Chairman | 46.24M | N/A | 1952 |
Ms. Cheung Ling Cheng | Executive Vice Chairwoman of the Board | 32.61M | N/A | 1964 |
Ms. Mingqin Li | Senior VP & Executive Director | 1.32M | N/A | 1959 |
Mr. Zhoushan Tian | Executive Director | 2M | N/A | 1964 |
Mr. Hsin Tse | Senior VP & Executive Director | 6.43M | N/A | 1970 |
Ms. Chun Ling Li | Chief Financial Officer | N/A | N/A | 1972 |
Sean Chen | Chief Strategy Officer | N/A | N/A | N/A |
Orphanides George | Chief Scientific Advisor of invoX | N/A | N/A | N/A |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection. It also provides surgery/analgesia medicines comprising Debaian cataplasms and Gaisanchun soft capsules; and cardio-cerebral vascular medicines, including Yilunping and Kaina tablets. In addition, the company is involved in the long term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Sino Biopharmaceutical Limited’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 4; Board: 2; Shareholder rights: 7; Compensation: 9.